Lurasidone - Medication and Pregnancy KB

Lurasidone

Exposed non-exposed, cohort studies

Study	Country Study period Study design	Data source	Exposure definition	Non-exposure definition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias
Cohen 2023	USA 2008 - 2021 prospective cohort	The National Pregnancy Registry for Psychiatric Medications, USA.	Pregnant women with first trimester (0 <= 13 weeks) use of Lurasidone.	unexposed, sick Pregnant women unexposed tp Second-generation antipsychotics (SGAs) during the entire pregnancy.	1st trimester	134 / 886	Univariate adjustments: choice to reporte results adjusted for alcohol use in 1st trimester.
Cohen 2023	USA 2008 - 2021 prospective cohort		Participants were interviewed by trained research staff via phone at three points across pregnancy: enrollment (any time during pregnancy), 7 months gestation, and 3 months postpartum. Interview collected notably information regarding pharmacotherapy before, during, and after pregnancy.		1st trimester	134 / 886
Kernizan 2019	USA 2014 - 2017 retrospective cohort	Retrospective cohort of patients referred to Maternal Fetal Care Center, St Louis, Missouri.	Pregnant women exposed to Lurasidone during pregnancy.	unexposed, sick Pregnant women not exposed to mood stabilizer during pregnancy.	during pregnancy (anytime or not specified)	24 / 140	For preterm and malfo: Overlapping Kernizan 2019 and 2024: use of Kernizan 2024 because full text publication (Abstract in 2019) => outcomes not reported here.
Kernizan 2019	USA 2014 - 2017 retrospective cohort		Not reported.		during pregnancy (anytime or not specified)	24 / 140
Kernizan (Controls exposed to LTG) 2024	USA 2014 - 2017 retrospective cohort	The Maternal and Fetal Care Center at SSM Health St. Mary's Hospital Center, Missouri, USA.	Pregnant women with a diagnosis of bipolar disorder who were prescribed lurasidone only at some point of their pregnancy.	exposed to other treatment, sick Pregnant women with a diagnosis of bipolar disorder who were prescribed lamotrigine only at some point of their pregnancy.	during pregnancy (anytime or not specified)	25 / 13
Kernizan (Controls exposed to LTG) 2024	USA 2014 - 2017 retrospective cohort		Analyzed clinical data extracted from the electronic medical records. Maternal information collected included bipolar treatment regimens at the first visit, throughout pregnancy, and at delivery and illicit drug use by the mother during pregnancy.		during pregnancy (anytime or not specified)	25 / 13
Kernizan (Controls unexposed, sick) 2024	USA 2014 - 2017 retrospective cohort	The Maternal and Fetal Care Center at SSM Health St. Mary's Hospital Center, Missouri, USA.	Pregnant women with a diagnosis of bipolar disorder who were prescribed lurasidone only at some point of their pregnancy.	unexposed, sick Pregnant women with a diagnosis of bipolar disorder who were not prescribed mood stabilizers (lithium, antiepileptics, atypical antipsychotics) at some point of their pregnancy.	during pregnancy (anytime or not specified)	25 / 139
Kernizan (Controls unexposed, sick) 2024	USA 2014 - 2017 retrospective cohort		Analyzed clinical data extracted from the electronic medical records. Maternal information collected included bipolar treatment regimens at the first visit, throughout pregnancy, and at delivery and illicit drug use by the mother during pregnancy.		during pregnancy (anytime or not specified)	25 / 139

Case-control studies

Study	Country Study period Study design	Data source	Case	Control	Exposition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias

Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;

Empty. There are no case-control studies available for this drug.

master protocol